NXTC
NextCure, Inc. (NASDAQ)
Healthcare — Biotechnology
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that is designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leukemic stem cells; NC181 a humanized antibody targeting ApoE4 for the treatment of Alzheimer's disease; and NC605 an antibody that targets Siglec-15, as well as chronic bone diseases, such as osteoarthritis and non-union fractures. The company also develop SIM0505, a novel antibody-drug conjugate (ADC) targeting CDH6 (cadherin-6 or K-cadherin) for the treatment of solid tumors. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.
Price History
Fundamentals
| Market Cap | $7.04M |
| P/E Ratio (TTM) | - |
| Forward P/E | -0.23 |
| EPS (TTM) | $-16.82 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | -132.41% |
| Debt/Equity | 18.39 |
| Recommendation | None |
| Analyst Target | $19.33 |
| Analysts | 3 |
| Indexes | NASDAQ |
Technical Indicators
| RSI (14) | 42.2 |
| Beta | 1.30 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $15.74 |
| 52-Week Low | $1.55 |
| 50-Day Avg | $6.24 |
| 200-Day Avg | $9.68 |
| Avg Volume | 100.5K |
| Volume | 78.0K |
Performance Analysis
NEUTRALNXTC presents a mixed picture with both positive and negative indicators.
Recent News
Last updated: Jul 02, 2026 13:23 UTC
Back to Screener Export Report